Cerus Corporation - Asset Resilience Ratio
Cerus Corporation (CERS) has an Asset Resilience Ratio of 23.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CERS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Cerus Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cerus Corporation total assets.
Liquid Assets Composition Over Time
This chart breaks down Cerus Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Cerus Corporation (CERS) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $52.58 Million | 23.59% |
| Total Liquid Assets | $52.58 Million | 23.59% |
Asset Resilience Insights
- Good Liquidity Position: Cerus Corporation maintains a healthy 23.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cerus Corporation Industry Peers by Asset Resilience Ratio
Compare Cerus Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Cerus Corporation (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Cerus Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.36% | $62.92 Million | $221.86 Million | -1.60pp |
| 2024-12-31 | 29.96% | $60.19 Million | $200.92 Million | +2.54pp |
| 2023-12-31 | 27.41% | $54.20 Million | $197.75 Million | -3.11pp |
| 2022-12-31 | 30.52% | $66.57 Million | $218.09 Million | -3.41pp |
| 2021-12-31 | 33.94% | $80.60 Million | $237.50 Million | -9.87pp |
| 2020-12-31 | 43.81% | $97.00 Million | $221.41 Million | +13.16pp |
| 2019-12-31 | 30.65% | $50.73 Million | $165.53 Million | -23.63pp |
| 2018-12-31 | 54.28% | $88.72 Million | $163.46 Million | +6.42pp |
| 2017-12-31 | 47.85% | $47.01 Million | $98.24 Million | +0.43pp |
| 2016-12-31 | 47.42% | $49.07 Million | $103.48 Million | +20.99pp |
| 2015-12-31 | 26.43% | $36.86 Million | $139.47 Million | -8.44pp |
| 2014-12-31 | 34.87% | $28.51 Million | $81.77 Million | +1.06pp |
| 2013-12-31 | 33.81% | $28.19 Million | $83.38 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $48.92 Million | -- |
| 2011-12-31 | 0.63% | $287.00K | $45.37 Million | -1.57pp |
| 2010-12-31 | 2.20% | $1.06 Million | $48.17 Million | -5.46pp |
| 2009-12-31 | 7.67% | $2.64 Million | $34.49 Million | -18.26pp |
| 2008-12-31 | 25.93% | $12.28 Million | $47.34 Million | -21.67pp |
| 2007-12-31 | 47.60% | $37.23 Million | $78.21 Million | +6.90pp |
| 2006-12-31 | 40.69% | $47.13 Million | $115.82 Million | -27.54pp |
| 2005-12-31 | 68.23% | $40.02 Million | $58.66 Million | +13.21pp |
| 2004-12-31 | 55.02% | $56.16 Million | $102.08 Million | -18.29pp |
| 2003-12-31 | 73.31% | $86.84 Million | $118.46 Million | +15.89pp |
| 2002-12-31 | 57.42% | $41.88 Million | $72.95 Million | +11.45pp |
| 2001-12-31 | 45.97% | $58.96 Million | $128.26 Million | +26.44pp |
| 2000-12-31 | 19.53% | $18.39 Million | $94.16 Million | -68.75pp |
| 1999-12-31 | 88.28% | $36.90 Million | $41.80 Million | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more